Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00847730
Other study ID # VACDrsg 2008-37
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2009
Est. completion date September 2009

Study information

Verified date July 2022
Source 3M
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is aimed at evaluating the clinician's perceived ease of using the V.A.C. GranuForm bride dressing and the patients perceived level of comfort during the dressing wear.


Description:

The objective of this study is to evaluate the ease of use of the V.A.C® GranuFoam™ Bridge dressing on Diabetic Foot Ulcers under ActiV.A.C® negative pressure wound therapy for a period of 48-72 hrs (+6hrs). Ease of use will be determined based on the feedback on the following characteristics 1) Ease of dressing application 2) Ease of dressing removal and 3) Ease of dressing conformability. Additionally patient feedback on comfort during wear will also be collected. Patients currently prescribed to V.A.C.® Therapy will be enrolled in the trial.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date September 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria 1. Male or Female subjects must be = 18 years of age 2. Subject is willing and able to provide written informed consent and comply with protocol required procedures 3. Subject has a calcaneal, dorsal or plantar diabetic foot ulcer no greater than a Grade 2 on the Wagner Grading System for which ActiV.A.C.® Therapy has been prescribed and requires off loading of the SensaT.R.A.C. PadTM 4. Subject has a foot ulcer that is = 1.5cm2 but no greater than 84 cm2 5. Female subject that is willing to use an effective method of contraception for the duration of the study, is permanently sterilized, or post-menopausal as defined by cessation of menses for at least twelve (12) months prior to enrollment. Acceptable means of contraception is defined as use of Birth control pills, Depo Provera® , Norplant® , IUD (intrauterine device), Diaphragm with spermicide, Condom with spermicide Exclusion Criteria 1. Subject's wound measures > 84 cm2 2. Presence of untreated cellulitis 3. Presence of untreated or refractory osteomyelitis (including untreated necrotic bone, non-viable tissue and infected bone) 4. History of radiation to the wound area 5. History of thermal injury in the wound area 6. Known hypersensitivity to any disposable component of the V.A.C.® Therapy system 7. Necrotic tissue with eschar present that cannot be debrided prior to subject enrollment in the study 8. Subject is exhibiting active signs and symptoms of infection of the wound(i.e. increased redness or erythema, increased pain, warmth, purulent drainage) 9. Past or current enrollment in this clinical study or any other clinical study within 30 days 10. Female Subject who is pregnant or is unwilling to use acceptable means of contraception during the duration of her participation in the study 11. Subject exhibits significant peri-wound issues that in the opinion of the investigator can interfere with the study assessments 12. Subject is unable to co-operate with study assessments or has a history of non-compliance with off-loading modalities or has a foot deformity that in the opinion of the investigator does not allow for appropriate dressing application or off loading placement.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
V.A.C. Negative Pressure Wound Therapy System
This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds

Locations

Country Name City State
United States Key Stone Medical Research Associates Bethlehem Pennsylvania
United States North American Center for Limb Preservation New Haven Connecticut
United States Alamo Clinical Research Consultants San Antonio Texas
United States Alamo Family Foot and Ankle Care San Antonio Texas
United States Drs Research Network South Miami Florida
United States Scott and White Dept of Surgery Temple Texas

Sponsors (1)

Lead Sponsor Collaborator
3M

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ease of Use Assessment Each subject was assessed on the three scales (each scale was 1-Poor, 2 - Fair, 3 - Good, 4 - Excellent) and given a score on each individual characteristic (Ease of Dressing Application, Ease of Conformability, and Ease of Dressing Removal). The scores were then summed for each subject with possible range being 3-12. If the subject had a total score greater than or equal to 6, and a minimum score of greater than or equal to 2 on each individual characteristic then the subject was included in the percentage of subjects with satisfactory performance. Note that for each scale higher scores indicate better outcomes. 48-72 hours (+6 hours) time period
See also
  Status Clinical Trial Phase
Completed NCT02652754 - Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers Phase 1
Completed NCT01070433 - A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers Phase 2
Completed NCT00971048 - Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds N/A
Terminated NCT00762138 - The AutoloGel™ Post-Market Surveillance (TAPS) Program N/A
Completed NCT00578604 - Non-Invasive Assessment of Wound Healing With Optical Methods N/A
Completed NCT05417425 - Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers Phase 1
Completed NCT02631512 - Evaluation of Woulgan in Diabetic Foot Ulcer Phase 4
Completed NCT02222376 - Effect of Topic Pirfenidone in Diabetic Ulcers Phase 3
Terminated NCT01816633 - Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers N/A
Completed NCT01454401 - LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers N/A
Completed NCT01221207 - Instant Total Contact Cast to Heal Diabetic Foot Ulcers N/A
Withdrawn NCT01105884 - Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers N/A
Completed NCT01291160 - Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers Phase 2/Phase 3
Completed NCT00536744 - Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers Phase 3
Terminated NCT00316537 - Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers Phase 1/Phase 2
Completed NCT00013299 - Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3 Phase 2
Completed NCT00013286 - A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk Phase 2
Terminated NCT02667327 - A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer Phase 3
Not yet recruiting NCT00916292 - Safety Study of Topical Human FGF-1 for Wound Healing Phase 1
Completed NCT01154374 - A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot) Phase 2